Related references
Note: Only part of the references are listed.Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells
Bian Hu et al.
HUMAN GENE THERAPY (2019)
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
Mohamad Hamieh et al.
NATURE (2019)
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Kurt A. Schalper et al.
NATURE MEDICINE (2019)
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F. Cloughesy et al.
NATURE MEDICINE (2019)
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Junfei Zhao et al.
NATURE MEDICINE (2019)
Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice
Muhua Chen et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment
Rut Tejero et al.
EBIOMEDICINE (2019)
Hypoxia Selectively Impairs CAR-T Cells In Vitro
Robert Berahovich et al.
CANCERS (2019)
An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma
Cyril Neftel et al.
CELL (2019)
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
Bryan D. Choi et al.
NATURE BIOTECHNOLOGY (2019)
Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma
Jing Cui et al.
NEURO-ONCOLOGY (2019)
B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma
Xin Tang et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells
Dong Yang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The efficacy of third generation anti-HER2 chimeric antigen receptor T cells in combination with PD1 blockade against malignant glioblastoma cells
Luxi Shen et al.
ONCOLOGY REPORTS (2019)
B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres
Dean Nehama et al.
EBIOMEDICINE (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment
Marina Martinez et al.
FRONTIERS IN IMMUNOLOGY (2019)
Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma
Kevin Bielamowicz et al.
NEURO-ONCOLOGY (2018)
CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells
In-Young Jung et al.
CANCER RESEARCH (2018)
Circulating tumor DNA dynamically predicts response and/or relapse in patients with hematological malignancies
Sousuke Nakamura et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
Jian Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma
Katarzyna C. Pituch et al.
MOLECULAR THERAPY (2018)
Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma
Christine E. Brown et al.
MOLECULAR THERAPY (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
The market for chimeric antigen receptor T cell therapies
Amy Yip et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-\-expressing artificial antigen presenting cells for adoptive cell therapy for glioma
Ayguen Sahin et al.
PLOS ONE (2018)
Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy
Serena Pellegatta et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma
Carter M. Suryadevara et al.
ONCOIMMUNOLOGY (2018)
Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy
Amber J. Giles et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized therapy
Michele Patrizii et al.
FRONTIERS IN ONCOLOGY (2018)
Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors
Pakawat Chongsathidkiet et al.
NATURE MEDICINE (2018)
Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell
Hua Jiang et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas
Yibo Yin et al.
MOLECULAR THERAPY-ONCOLYTICS (2018)
Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors
LingLi Yan et al.
OncoTargets and Therapy (2018)
Fluorine-19 MRI for detection and quantification of immune cell therapy for cancer
Fanny Chapelin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma
Bryan G. Harder et al.
FRONTIERS IN ONCOLOGY (2018)
Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity
Dongrui Wang et al.
JCI INSIGHT (2018)
NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma
Tobias Weiss et al.
CANCER RESEARCH (2018)
NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma
Tobias Weiss et al.
CLINICAL CANCER RESEARCH (2018)
Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
Jiangtao Ren et al.
CLINICAL CANCER RESEARCH (2017)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape
Benjamin M. Ellingson et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O'Rourke et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Waseem Qasim et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
Thomas Shum et al.
CANCER DISCOVERY (2017)
Culture conditions defining glioblastoma cells behavior: what is the impact for novel discoveries?
Pitia Flores Ledur et al.
ONCOTARGET (2017)
Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the Migrating Front of Human Glioblastoma
Spyros Darmanis et al.
CELL REPORTS (2017)
Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants
Giedre Krenciute et al.
CANCER IMMUNOLOGY RESEARCH (2017)
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial
Nabil Ahmed et al.
JAMA ONCOLOGY (2017)
Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy
Praveen Sridhar et al.
CANCERS (2017)
Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors
Joerg Felsberg et al.
CLINICAL CANCER RESEARCH (2017)
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape (Publication with Expression of Concern. See vol. 129, pg. 3464, 2019)
Meenakshi Hegde et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response
Richard P. Junghans et al.
PROSTATE (2016)
Toxicity and management in CAR T-cell therapy
Challice L. Bonifant et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts
John W. Cassidy et al.
CANCER RESEARCH (2015)
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Christine E. Brown et al.
CLINICAL CANCER RESEARCH (2015)
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
Steven C. Katz et al.
CLINICAL CANCER RESEARCH (2015)
Prospective glioma grading using single-dose dynamic contrast-enhanced perfusion MRI
K. K. Jain et al.
CLINICAL RADIOLOGY (2015)
Conserved and divergent aspects of human T-cell development and migration in humanized mice
Joanna Halkias et al.
IMMUNOLOGY AND CELL BIOLOGY (2015)
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The role of regulatory T cells and microglia in glioblastoma-associated immunosuppression
Alfred P. See et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Hideho Okada et al.
LANCET ONCOLOGY (2015)
The pharmacology of second-generation chimeric antigen receptors
Sjoukje J. C. van der Stegen et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia
Cameron J. Turtle et al.
BLOOD (2015)
Immunocompetent murine models for the study of glioblastoma immunotherapy
Taemin Oh et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Anoop P. Patel et al.
SCIENCE (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
EGFR Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing
Joshua M. Francis et al.
CANCER DISCOVERY (2014)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered
Hui K. Gan et al.
FEBS JOURNAL (2013)
Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres
Monica Patane et al.
MOLECULAR CANCER (2013)
T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma
Kevin K. H. Chow et al.
MOLECULAR THERAPY (2013)
Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
Cor H. J. Lamers et al.
MOLECULAR THERAPY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms
C. A. Del Vecchio et al.
ONCOGENE (2013)
Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody
Bryan D. Choi et al.
CANCER IMMUNOLOGY RESEARCH (2013)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N. Kochenderfer et al.
BLOOD (2012)
Glioblastoma Stem-like Cell Lines with Either Maintenance or Loss of High-Level EGFR Amplification, Generated via Modulation of Ligand Concentration
Alexander Schulte et al.
CLINICAL CANCER RESEARCH (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
Chrystal U. Louis et al.
BLOOD (2011)
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Renier J. Brentjens et al.
BLOOD (2011)
In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)
De-Gang Song et al.
CANCER RESEARCH (2011)
Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme
Marie-Therese Stockhausen et al.
EXPERIMENTAL CELL RESEARCH (2011)
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group
Kenneth J. Cohen et al.
NEURO-ONCOLOGY (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Pseudoprogression Following Chemoradiotherapy for Glioblastoma Multiforme
Paul Sanghera et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2010)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
Vaccine provides new hope for patients with deadly brain cancer
[Anonymous]
FUTURE NEUROLOGY (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
John H. Sampson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The promise and potential pitfalls of chimeric antigen receptors
Michel Sadelain et al.
CURRENT OPINION IN IMMUNOLOGY (2009)
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Michael C. Milone et al.
MOLECULAR THERAPY (2009)
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Brian G. Till et al.
BLOOD (2008)
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Martin A. Pule et al.
NATURE MEDICINE (2008)
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression
Marianela Candolfi et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Expression of interleukin-13 receptor α2 in glioblastoma multiforme:: Implications for targeted therapies
John S. Jarboe et al.
CANCER RESEARCH (2007)
CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles
Dagmar Beier et al.
CANCER RESEARCH (2007)
Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma
Julie R. Park et al.
MOLECULAR THERAPY (2007)
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells
Claudia M. Kowolik et al.
CANCER RESEARCH (2006)
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw et al.
CLINICAL CANCER RESEARCH (2006)
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines
Jeongwu Lee et al.
CANCER CELL (2006)
EphA2 as a glioma-associated antigen: A novel target for glioma vaccines
M Hatano et al.
NEOPLASIA (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Identification of human brain tumour initiating cells
SK Singh et al.
NATURE (2004)
Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors
MS Lesniak et al.
JOURNAL OF NEURO-ONCOLOGY (2004)
Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study
B Badie et al.
JOURNAL OF NEUROSURGERY (2000)
Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen
W Debinski et al.
MOLECULAR MEDICINE (2000)
Share Paper
